Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 0.78 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.78 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Denufosol SCHEMBL24414847 | 0.88 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL15108954 | 0.88 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL30480354 | 0.88 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL22127329 | 0.88 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL561652 | 0.87 | P2RY2 (0.98) | P2RY2P2RY4P2RY6 | |
| SCHEMBL19101684 | 0.85 | POLB (0.69) | P2RY2P2RY4P2RY6POLB | |
| SCHEMBL30111010 | 0.84 | P2RY2 (0.86) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL29798782 | 0.84 | P2RY2 (0.86) | P2RY2P2RY4P2RY6P2RY14 | |
| Cytarabine 5'-Phosphate SCHEMBL25290865 | 0.84 | P2RY2 (0.89) | P2RY2P2RY4P2RY6 | |
| Denufosol SCHEMBL29366605 | 0.82 | P2RY2 (1.00) | P2RY2P2RY4P2RY6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-11-16 | — | — | US | disclosed |
| EP-2914248-B2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230210839-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| EP-3925607-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11564916-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4005559-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIODIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220031679-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210340128-A1 | Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl)-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)Cyclopropanecarboxamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-11-04 | — | — | US | disclosed |
| US-11147770-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-19 | — | — | US | disclosed |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2012027247-A2 | PHARMACEUTICAL COMPOSITION OF (R)-1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXY PROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL) CYCLOPROPANECARBOXAMIDE AND ADMINISTRATION THEROF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100256184-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010078103-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100168094-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010048564-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100074949-A1 | Pharmaceutical composition and administration thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256184-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CYP3A5, CYP4B1, CYP3A4 | P2RY2 246/4885P2RY4 102/4885P2RY6 433/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | P2RY2 294/4885P2RY4 325/4885P2RY6 343/4885 |
| US-20100113508-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1G, SCNN1B | P2RY2 80/4885P2RY4 96/4885P2RY6 160/4885 |
| US-20120122921-A1 | PROCESS FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, TMEM109 | P2RY2 922/4885P2RY4 976/4885P2RY6 1344/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | P2RY2 148/4885P2RY4 149/4885P2RY6 186/4885 |
| US-20220031679-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID AND ADMINISTRATION THEREOF | CFTR, GLI2, GPR39 | P2RY2 169/4885P2RY4 241/4885P2RY6 143/4885 |
| US-20210340128-A1 | Solid Forms of (R)-1(2,2-Difluorobenzo[D][1,3]Dioxol-5-yl)-N-(1-(2,3-Dihydroxypropyl)-6-Fluoro-2-(1-Hydroxy-2-Methylpropan-2-yl)-1H-Indol-5-yl)Cyclopropanecarboxamide | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR1A, HTR1D | P2RY2 622/4885P2RY4 1271/4885P2RY6 1813/4885 |
| US-20100074949-A1 | Pharmaceutical composition and administration thereof | CYP3A5, CYP3A4, CYP4B1 | P2RY2 203/4885P2RY4 82/4885P2RY6 319/4885 |
| US-20100168094-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC2 | P2RY2 167/4885P2RY4 196/4885P2RY6 277/4885 |
| US-11147770-B2 | Pharmaceutical composition and administrations thereof | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | P2RY2 566/4885P2RY4 186/4885P2RY6 957/4885 |
| US-20230364073-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | CFTR, CLCN2, CLIC1 | P2RY2 126/4885P2RY4 176/4885P2RY6 130/4885 |
| US-20230210839-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CYP3A5, CYP4B1, CYP3A4 | P2RY2 246/4885P2RY4 102/4885P2RY6 433/4885 |
| US-20100113509-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | P2RY2 80/4885P2RY4 96/4885P2RY6 160/4885 |
| US-11564916-B2 | Pharmaceutical composition and administrations thereof | CYP3A5, CYP4B1, CYP3A4 | P2RY2 246/4885P2RY4 102/4885P2RY6 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.